Featured
The Lancet
Diabetes & Endocrinology: Published: March, 2024Atherosclerotic cardiovascular
disease is a leading cause of death worldwide, and LDL cholesterol is a major
causal risk factor.Diabetes substantially increases
the risk of atherosclerotic cardiovascular disease.TAKE-HOME MESSAGEIn this
participant-level meta-analysis of 19 trials, sta...
Journal of Diabetes and its Complications: September
2023Kidney disease is a diabetes-related
complication and diabetes is the most common cause of end-stage kidney disease
(ESKD) in the world.This study analyzed the incidence of kidney disease in the
Diabetes Prevention Program Outcomes Study.TAKE-HOME MESSAGEAfter 21
years of randomization i...
Diabetes, Obesity &
Metabolism Journal: Published:
December 2023Type 2 diabetes (T2D) and liver diseases are closely
associated. T2D is an independent risk factor for chronic liver diseases,
including metabolic dysfunction-associated steatotic liver disease (MASLD),
non-alcoholic steatohepatitis, cirrhosis and hepatocellular carcinoma...
The Lancet Diabetes
& Endocrinology: Published
December, 2023Inflammation has been implicated in the pathogenesis of
diabetes. This study investigated the randomised treatment effect of low-dose
aspirin on incident type 2 diabetes and fasting plasma glucose (FPG)
concentrations among older adults.TAKE-HOME MESSAGEThis post hoc analysis of...
Journal of Diabetes and its Complications: August 2023Nearly one out of three individuals will develop a
psychiatric disorder during their life. Severe psychiatric disorders are
associated with higher mortality rates, with 10–20 life-years lost compared to
individuals without a severe psychiatric disorderSeveral psychiatric disorders are li...
Diabetes Care Journal (ADA): August, 2023Early identification of patients
with type 2 diabetes who are at risk of kidney disease progression is
particularly important in the context of new glucose-lowering medications such
as sodium-glucose cotransporter 2 (SGLT2) inhibitor (Dapagliflozin, Canagliflozin,
Empagliflozin, Ertugliflozin) that can m...
ADA Journal: Diabetes Care: July, 2023Diabetes can be diagnosed by demonstrating increased
concentrations of glucose in venous plasma or increased hemoglobin A1c (HbA1c)
in the blood. Glycemic control is monitored by the people with diabetes
measuring their own blood glucose with meters and/or with continuous
interstitial glucose monitorin...
Diabetes
Care: Diabetes Journal: July, 2023Dietary sugars are associated with
various health issues, including overweight, obesity, cardiovascular diseases
(CVDs), and type 2 diabetes (T2D). Manufacturers have proposed
alternatives to reduce added sugars, notably by substituting artificial
sweeteners (e.g., aspartame, acesulfame potassium [K],...
Diabetes Care: May, 2023Type 2 diabetes is associated with
increased risk of microvascular and macrovascular disease, with the risk of
cardiovascular (CV) mortality more than double in people with type 2 diabetes
compared with those without. In the last decade, large dedicated
CV outcome trials in people with type 2 diabetes and at high risk or...
Diabetes Research and Clinical Practice: November
21, 2022The relationship between serum uric
acid levels and incident type 2 diabetes remains controversial.This cohort study assessed the
association between serum uric acid levels and the incidence of type 2 diabetes
in a Japanese population. TAKE-HOME MESSAGEThere was no significant
associati...
ADA: Diabetes Journals: Published June 2023Diabetes mellitus (DM) is one of the most important causes of
CKD. Moreover, both DM and CKD are important risk factors for cardiovascular
disease (CVD). Metformin is still the first-line drug for DM management. The
concern, of course, is an increased risk of metformin-associated lactic
acidosis (MALA)...
